Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer

Authors:

Abstract
No abstract available
Funding Information
  • Pfizer Japan
  • Ono Pharmaceutical
  • Cancer Research Institute
  • Chugai Pharmaceutical
  • Bristol-Myers Squibb
  • Merck Sharp and Dohme K.K.
  • AstraZeneca
  • Eli Lilly Japan
  • Astellas Pharma
  • Taiho Pharmaceutical
  • Teijin Pharma
  • Boehringer Ingelheim
  • Japan Society for the Promotion of Science (16H05308)
  • Takeda Pharmaceutical Company
  • Daiichi Sankyo Company
  • Novartis Pharma
  • Kanazawa Medical University
  • Japan Agency for Medical Research and Development (16cm0106513h0001)
  • Cancer Research Institute, Kanazawa University
  • Roche
  • Kanazawa University (160304ZZH2190202)
  • Novartis

This publication has 41 references indexed in Scilit: